Maravai LifeSciences Holdings, Inc. Class A

XNASHealth care

Last traded price · USD

$7.85

+5.37%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $7.73
Previous close: $7.45
Volume: 3.6M
Day's high: $7.89
Day's low: $7.28

In brief

Maravai LifeSciences Holdings, Inc. is a health care company listed on Nasdaq, valued at about $1.17B.
Its shares closed at $7.72 on 4 Nov 2026, up 169.0% over the past year.
From India you can buy MRVI in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Maravai LifeSciences Holdings, Inc. (MRVI) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole MRVI share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade MRVI options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.7% (SPY −1.6%, XLV +13.5%). 3 months: +20.4% (SPY −0.4%, XLV +15.5%). 1 year: +169.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MRVI, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $7.72 was 4.0% above its 50-day average ($7.42) and 45.9% above its 200-day average ($5.29). It has closed above the 200-day for 143 sessions, since 14 Apr 2026. The 50-day average crossed above the 200-day on 24 Oct 2025, 258 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
75% of the way up its 52-week range
Closed at $7.72 on 4 Nov 2026: 18.0% below the 52-week high of $9.42 (26 Aug 2026) and 203.3% above the low of $2.55 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.0% of shares outstanding
13.3M shares were sold short at the 15 Oct 2026 settlement, 9.0% of the 149.0M shares outstanding; covering them would take 4.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.7%

6 months+95.9%

1 year+169.0%

5 years−82.8%

Newswire

About

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Website

Notable moves

November 8, 2024
−35.27%
February 23, 2024
+63.60%
November 8, 2023
−31.69%

Newswire

About

Website

Notable moves

November 8, 2024
−35.27%
February 23, 2024
+63.60%
November 8, 2023
−31.69%

Maravai LifeSciences Holdings, Inc. Class A

XNASHealth care

Last traded price · USD

$7.85

+5.37%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $7.73
Previous close: $7.45
Volume: 3.6M
Day's high: $7.89
Day's low: $7.28

In brief

Maravai LifeSciences Holdings, Inc. is a health care company listed on Nasdaq, valued at about $1.17B.
Its shares closed at $7.72 on 4 Nov 2026, up 169.0% over the past year.
From India you can buy MRVI in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Maravai LifeSciences Holdings, Inc. (MRVI) shares from India?

Do I need the price of a whole MRVI share to invest?

How much can I invest in US stocks in a year?

Can I trade MRVI options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.7% (SPY −1.6%, XLV +13.5%). 3 months: +20.4% (SPY −0.4%, XLV +15.5%). 1 year: +169.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MRVI, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $7.72 was 4.0% above its 50-day average ($7.42) and 45.9% above its 200-day average ($5.29). It has closed above the 200-day for 143 sessions, since 14 Apr 2026. The 50-day average crossed above the 200-day on 24 Oct 2025, 258 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
75% of the way up its 52-week range
Closed at $7.72 on 4 Nov 2026: 18.0% below the 52-week high of $9.42 (26 Aug 2026) and 203.3% above the low of $2.55 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.0% of shares outstanding
13.3M shares were sold short at the 15 Oct 2026 settlement, 9.0% of the 149.0M shares outstanding; covering them would take 4.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.7%

6 months+95.9%

1 year+169.0%

5 years−82.8%

Newswire

About

Website

Notable moves

November 8, 2024
−35.27%
February 23, 2024
+63.60%
November 8, 2023
−31.69%

Newswire

About

Website

Notable moves

November 8, 2024
−35.27%
February 23, 2024
+63.60%
November 8, 2023
−31.69%

Maravai LifeSciences Holdings, Inc. Class A

Maravai LifeSciences Holdings, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

75% of the way up its 52-week range

Short interest at 9.0% of shares outstanding

Maravai LifeSciences Holdings, Inc. Class A

Maravai LifeSciences Holdings, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

75% of the way up its 52-week range

Short interest at 9.0% of shares outstanding